H.H. Fiebig

BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.

C. Manzotti, Graziella Pratesi, E. MENTA et al. · PubMed · 2000 · 173 citations

Tumor Biology, Particular Cisplatin, Oncology +14

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

Markus Drees, W. A. Dengler, Thomas Roth et al. · PubMed · 1997 · 140 citations

Tumor Xenografts, Antitumor Activity, Pharmacotherapy +17

EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

Hans R. Hendriks, P. E. Pizao, Dan Berger et al. · European Journal of Cancer · 1993 · 104 citations

Tumor Biology, Preclinical Models, Medicine +7

Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

Epie Boven, Benjamin Winograd, Delaney Berger et al. · PubMed · 1992 · 87 citations

Preclinical Therapeutics, Chemoprevention Strategy, European Joint Project +18

Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds

Sylvie M. Guichard, R. W. Else, Eilidh M. Reid et al. · Biochemical Pharmacology · 2005 · 77 citations

Inorganic Compound, Chemical Engineering, Coordination Complex +8